Page 70 - ARNM-1-2

Advances in Radiotherapy
& Nuclear Medicine Immunochemoradiotherapy in malignant pleural mesothelioma

68
18 F-FAPI-42 and Ga-FAPI-04 exhibit similar detection All authors contributed to the article and approved the
capabilities , suggesting that F-FAPI-42 holds promise submitted version.
18
[18]
for the detection and evaluation of malignant pleural
mesothelioma. However, to our best knowledge, few Ethics approval and consent to participate
studies have investigated the use of F-FAPI PET/CT in The studies involving human participants were reviewed
18
malignant mesothelioma. This study represents the first and approved by the Harbin Medical University Cancer
case of employing F-FDG PET/CT and F-FAPI-04 Hospital Medical Ethics Committee. The ethics committee
18
18
PET/CT dual imaging to evaluate the efficacy of added the requirement of written informed consent for
immunochemotherapy combined with radiotherapy and participation.
to distinguish between benign and malignant lymph nodes
in malignant pleural mesothelioma. It is worth noting Consent for publication
that although studies have indicated that lymph node The human subjects involved in this article agreed in
metastatic lesions generally exhibit FAPI uptake, some writing, and we obtained approval to release the data and
other studies have reported a lack of FAPI uptake in lymph
node metastatic lesions after treatment . This suggests images.
[19]
the need for caution when identifying this possibility. Availability of data
4. Conclusion The datasets generated during and analyzed during the
current study are not publicly available due to patient
18
Our case demonstrates the potential of F-FDG PET/CT
in the diagnosis of pleural mesothelioma. Furthermore, privacy concerns but are available from the corresponding
it suggests that F-FAPI-04 PET/CT has the potential to author upon reasonable request.
18
effectively evaluate the effects of immunochemotherapy. References
Notably, both F-FDG PET/CT and F-FAPI-04 PET/CT
18
18
may offer the capability to differentiate between benign 1. Hathi DK, Jones EF, 2019, 68Ga FAPI PET/CT: Tracer uptake
and malignant lymph nodes. in 28 different kinds of cancer. Radiol Imaging Cancer, 1:
e194003.
Acknowledgments https://doi.org/10.1148/rycan.2019194003
The authors would like to thank the participating patient, 2. Mona CE, Benz MR, Hikmat F, et al., 2022, Correlation of
as well as the colleagues and nurses who made this work 68Ga-FAPi-46 PET biodistribution with FAP expression
possible. by immunohistochemistry in patients with solid cancers:
Interim analysis of a prospective translational exploratory
Funding study. J Nucl Med, 63: 1021–1026.
This paper is supported by the National Natural Science https://doi.org/10.2967/jnumed.121.262426
Foundation of China General Projects (81571740) (KW); 3. Giesel FL, Kratochwil C, Schlittenhardt J, et al., 2021, Head-
Provincial Key Research and Development Program of to-head intra-individual comparison of biodistribution
Heilongjiang Province (GA21C001) (KW); Postdoctoral and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in
Special Scientific Research Grant of Heilongjiang Provincial cancer patients. Eur J Nucl Med Mol Imaging, 48: 4377–4385.
Government (LBH-Q17104) (KW); Distinguished Young https://doi.org/10.1007/s00259-021-05307-1
Scientist Funding of Harbin Medical University Affiliated
Tumor Hospital (JCQN2019-02); and Key Project of 4. Gundogan C, Guzel Y, Komek H, et al., 2022, 68Ga-FAPI-04
the Climbing Funding of the National Cancer Center PET/CT versus 18F-FDG PET/CT in malignant peritoneal
mesothelioma. Clin Nucl Med, 47: e113–e115.
(NCC201808B019).
https://doi.org/10.1097/RLU.0000000000003858
Conflict of interest 5. Kessler L, Ferdinandus J, Hirmas N, et al., 2022, 68Ga-FAPI

The authors report no conflict of interest in this paper. as a diagnostic tool in sarcoma: Data from the 68Ga-FAPI
PET prospective observational trial. J Nucl Med, 63: 89–95.
Author contributions https://doi.org/10.2967/jnumed.121.262096
Conceptualization: Mengye Peng 6. Treglia G, Muoio B, Roustaei H, et al., 2021, Head-to-head
Methodology: Menglu Wang, Ying Zhang, Tingting Wu comparison of fibroblast activation protein inhibitors (FAPI)
Writing - original draft: Mengye Peng radiotracers versus [18F]F-FDG in oncology: A systematic
Writing – review & editing: Kezheng Wang review. Int J Mol Sci, 22: 11192.

Volume 1 Issue 2 (2023) 4 https://doi.org/10.36922/arnm.0963